It is unclear if habituation of hindbrain A2 metabolo-sensory neurons to recurrent insulin-induced hypoglycemia (RIIH) correlates with estradiol-dependent adjustments in energy metabolism that favor positive energy balance. Laser-microdissected A2 cells from estradiolor oil-implanted ovariectomized female rats were analyzed by Western blot to assess effects of three prior daily insulin injections on basal and hypoglycemic patterns of catecholamine biosynthetic enzyme dopamine-beta-hydroxylase (DβH) and rate-limiting energy pathway enzyme protein expression. Precedent hypoglycemia respectively decreased or increased baseline DβH expression in estradiol-(E) vs. oil (O)-treated rats; this protein profile was further suppressed or augmented in those animals at 2 hr after re-induction of hypoglycemia. These data suggest that estradiol may curtail A2 noradrenergic-controlled functions both in the midst of and between hypoglycemic bouts. Results also show that prior hypoglycemia exposure upregulated A2 neuron glycolytic enzyme protein levels when E was present, and exerted differential effects on basal and hypoglycemia-associated respiratory chain and fatty acid synthetic pathway enzyme expression. E may thus accordingly amplify glycolysis-derived metabolites/energy, coupled with reduced reliance on oxidative phosphorylation, and activate the fatty acid synthetic pathway during RIIH. E may also be of benefit by preventing maladaptive reductions in A2 neuron Krebs cycle/electron transport enzyme expression during re-exposure to hypoglycemia. Augmentation of negative energy balance during this recurring metabolic stress in the absence of E is a likely impetus for augmented vs. decreased A2 signaling of energy imbalance by DβH in O vs. E rats during RIIH.
INTRODUCTION
Hindbrain noradrenergic neurons, including the A2 cell group located in the caudal dorsal vagal complex (cDVC), are involved in neural regulation of a wide array of physiological, behavioral and cognitive functions that maintain homeostasis, including control of emotional, endocrine, and autonomic responses to stress (Rinaman 2011) . A2 noradrenergic neurons are implicated in metabolo-sensory function by characteristic biomarker expression, including glucokinase (Briski et al. 2009 ), the ATP-dependent potassium channel, K ATP (Briski et al. 2009) , and the ultra-sensitive energy gauge adenosine 5'-monophosphate-activated protein kinase (AMPK) Briski 2011, 2012) . Evidence for glucose antimetabolite-induced increases in Fos protein (Briski and Marshall 2000) and dopamine-β-hydroxylase (DβH) mRNA (Li et al. 2006 ) expression by A2 neurons provides proof of functional susceptibility to glucoprivation. A2 cells communicate hypoglycemia-associated cell energy imbalance to the brain gluco-regulatory network as insulin-induced hypoglycemia-associated patterns of hypothalamic metabolo-sensory neuron AMPK activation, hypothalamic metabolic effector transmitter expression, and hypoglycemic hyperphagia are normalized by substrate fuel repletion of the cDVC (Gujar et al. 2014) . Indeed, recent studies show that lactoprivic signaling from hindbrain to hypothalamus is selectively performed by A2 neurons (Shrestha et al. 2014) . Insulin-dependent diabetes mellitus management is complicated by unremitting iatrogenic hypoglycemia and associated risk of brain dysfunction and injury. Evidence that hypoglycemia-induced transcriptional activation in the male rat DVC is diminished by precedent exposure (Paranjape and Briski 2005) prompts speculation that metabolo-sensory function in that site may be vulnerable to maladaptive desensitization to hypoglycemia (Smith and Amiel 2002) .
The ovarian hormone estradiol is a potent stimulus for energy metabolism, enhancing substrate catabolism and oxidative respiration in the brain during bio-energetic instability due to stroke (Chen et al. 2009 ). Estradiol is neuroprotective against singular bio-energetic insults, but the impact of this hormone on neuron energy metabolism during recurring hypoglycemia is unclear. Estradiol delivery to the ovariectomized (OVX) female rat caudal hindbrain sustains uniformity of glycemic responses to repeated insulin dosing while vehicle controls exhibit delayed recovery from recurring hypoglycemia (Nedungadi and Briski 2012) . Moreover, estradiol prevents habituation of hypoglycemia-associated nerve cell Fos immunostaining in the DVC (Nedungadi et al. 2006) . Estradiol may thus prevent cellular energy state adjustments over serial hypoglycemic bouts or, alternatively, may mask acquired cellular energy instability by promoting signals of energy balance. A2 neurons are likely direct targets for estradiol regulatory actions as these cells express estrogen receptor-alpha and -beta proteins (Ibrahim et al. 2013) . The current studies investigated the hypothesis that estradiol regulation of recurring hypoglycemia on A2 catecholamine neurotransmitter synthesis correlates with neuro-protective effects on energy metabolic pathway function during and between bouts of hypoglycemia. This work had two aims: 1) to determine how precedent hypoglycemia influences between-hypoglycemia baseline expression of the catecholamine biosynthetic enzyme DβH and key metabolic enzyme proteins and 2) to ascertain how habituated basal profiles of these proteins react to re-induction of hypoglycemia. Individual A2 neurons were identified in situ by immunocytochemistry and laser-catapult microdissected from brains of estradiol-vs. vehicle-implanted OVX rats after recovery from serial bouts of insulin-induced hypoglycemia or during re-exposure to hypoglycemia. Pooled A2 cells were evaluated by high-sensitivity Western blotting to determine expression of rate-limiting metabolic, e.g. glycolytic, tricarboxylic acid cycle, respiratory chain, and oxidative phosphorylation, acetyl-CoA carboxylase-AMPK-fatty acid synthase pathway, and DβH enzyme protein expression between and during bouts of recurring hypoglycemia.
METHODS AND MATERIALS

Animals
Adult female Sprague Dawley rats (225-250 g bw) were housed in groups of 2-3 per cage under a 14 hr light: 10 hr dark schedule (lights on at 05.00 hr), and gentled by daily handling. Rats were obtained from the ULM School of Pharmacy Vivarium in-house breeding colony; breeders were purchased from Harlan Laboratories, Inc. Rats had unrestricted access to standard laboratory chow and water.
All animal protocols were conducted in accordance with National Institutes of Health guidelines for care and use of laboratory rodents, and approved by the ULM Institutional Animal Care and Use Committee. On day 1, rats were anesthetized with ketamine/xylazine (0.1 mL/100 g bw sc; 90 mg ketamine: 10 mg xylazine/mL; Henry Schein Inc., Melville, NY), then bilaterally OVX and implanted with a subcutaneous (sc) capsule (i.d. 1.58 mm, o.d. 3 .18 mm; 10 mm/100 g bw) filled with 17β estradiol-3-benzoate (E; 30 µg/mL safflower oil) or oil (O) (Briski et al. 2001 ). This hormone replacement strategy results in circulating plasma estradiol concentrations that mimic endogenous hormone concentrations measured on metestrus in 4-day (Butcher et al. 1974) or on diestrus day-2 in 5-day cycling rats (Goodman 1978) . After surgery, rats were transferred to individual cages.
Experimental design
At 11.00 hr on days 6-8, groups of estradiol-and oil-implanted OVX rats were injected sc with neutral protamine Hagedorn insulin (I; 12.5 U/kg/mL sc; Henry Schein Inc.; n=8 E-implanted; n=8 O-implanted) or vehicle (V; n=4 E-implanted; n=4 O-implanted). At 11.00 hr on day 9, unfasted rats previously injected with V, one dose per day, on three previous days, received a final/fourth injection of V [n=4 E-implanted (E-V (Fig. 1 ). E-V 4 and O-V 4 groups were included in the design in order to assess effects of precedent hypoglycemia on baseline patterns of protein expression. Trunk blood and brain tissue were collected at 13.00 hr, at time point that coincides with the glucose nadir achieved by this insulin treatment paradigm Briski 2005, Nedungadi et al. 2006 ). Rats were killed by rapid decapitation, a method approved by American Veterinary Medical Association Guidelines on Euthanasia (AVMA 2013). Dissected hindbrains were snap-frozen in liquid nitrogen-cooled isopentane.
Western blot analysis of A2 nerve cell and cDVC metabolic and neurotransmitter biosynthetic enzyme protein expression Serial 10 µm frozen sections of the cDVC (−14.36 to −14.86 mm posterior to bregma) were cut in a cryostat and processed for tyrosine hydroxylase (TH)-immunoreactivity (-ir) (Ibrahim et al. 2013) . Only TH-ir-positive neurons characterized by an intact, visible nucleus and complete staining of the cytoplasmic compartment were individually removed from tissue sections using a P.A.L.M. UV-A microlaser (Carl Zeiss Microimaging, Inc., Thornwood, NY). The cDVC was bilaterally removed from serial 200 µm frozen hindbrain sections obtained from additional rats (n=4/treatment combination), using calibrated hollow micropunch needles (Stoelting, Inc., Kiel, WI); micropunched tissue was pooled for each rat. For each protein of interest, n=50 TH-ir cells per treatment group (12-13 cells/protein/ rat; n=4 rats/treatment group) were collected in lysis buffer for immunoblotting; each protein was analyzed in triplicate in separate lysate pools. cDVC aliquots from each rat were pooled within each treatment group; pyruvate dehydrogenase (PDH), succinate dehydrogenase (SDH), and oxidative phosphorylation enzyme complexes were independently evaluated in triplicate in separate sample pools. Protein separation and transblotting were performed as described Briski 2011, 2012 
Blood analyte measurements
Blood glucose concentrations were measured with an AccuCheck Advantage glucometer (Roche diagnostics, Indianapolis, IN), as described . Plasma estradiol concentrations were determined by radioimmunoassay, as reported (Briski et al. 2001 ); assay sensitivity is approximately 1.5 pg/mL, with intra-and inter-assay variabilities of 4.2 and 6.9%.
Statistics
Mean circulating glucose and estradiol concentrations and normalized protein O.D. measures were evaluated by two-way ANOVA and Student-Newman-Keuls post-hoc test. Differences of p<0.05 were considered significant. (Fig. 3A) ; the PDH subunit protein, E2/E3pb (Fig. 3B) ; tricarboxylic acid cycle enzymes, IDH2 ( Fig. 3C ) and OGDH (Fig. 3D) ; the respiratory chain Complex II protein subunit, C-V-alpha (Fig. 3E) , and ATP synthase-α ( Fig. 3F) Insulin dosing on days 1-3 correspondingly increased or decreased this protein in E-I 3 V or O-I 3 V. Insulin injection on day 4 further inhibited or augmented this profile in E-I 4 and O-I 4 , respectively.
RESULTS
Fig
DISCUSSION
The current studies investigated the hypothesis that estradiol regulation of recurring hypoglycemia on A2 catecholamine neurotransmitter synthesis correlates with neuro-protective effects of this hormone on energy metabolic pathway function during and between bouts of hypoglycemia. Precedent exposure to serial bouts of hypoglycemia caused opposite changes in basal A2 neuron DβH protein expression in estradiol-vs. oil-implanted OVX female rats, plus exacerbation of these divergent adjustments by renewed hypoglycemia. As these cells communicates hypoglycemia-associated cell energy imbalance signaling (Gujar et al. 2014; Shrestha et al. 2014) , estradiol-dependent adaptive down-regulation of noradrenergic neurotransmission by A2 neurons implies that this hormone may promote a positive energy state during this recurring metabolic stress. Estradiol also regulates effects of recurrent hypoglycemia on enzyme proteins involved in energy metabolism and fatty acid synthesis. As A2 cells exhibit elevated baseline expression of the rate-limiting glycolytic enzyme PFKL in the aftermath of hypoglycemia, coincident with diminished C-V-alpha and ATP synthase-α protein profiles, estradiol may stimulate glycolysis, yet suppress mitochondrial aerobic respiration/energy production. During the fourth of four daily hypoglycemic episodes, estradiol permitted OGDH up-regulation and prevented down-regulation of ATP synthase-α, implying that it may beneficially alleviate energy state negativity in A2 cells during re-exposure to this stress. This view is bolstered by evidence that A2 AMPK activation is greater in O vs. E rats in response to recurring hypoglycemia. Taken together, current data suggest that estradiol-mediated reductions in A2 noradrenergic signaling may reflect, in part, energetic resilience of these cells to recurring hypoglycemia. Further research is needed to determine effects of adaptive adjustments in between-hypoglycemia A2 neurotransmission on glucostatic and non-glucostatic functions governed by this cell group.
Acclimation of rate-limiting glycolytic, tricarboxylic acid cycle, and respiratory chain enzyme protein expression to hypoglycemia in A2 neurons: impact of estradiol
Precedent hypoglycemia exerts divergent, e.g. stimulatory or inhibitory effects on A2 PFKL vs. C-V-alpha and ATP synthase-α protein profiles in the E-I 3 V treatment group. Adaptive augmentation of baseline PFKL expression reported here is accompanied by a loss of this positive reaction to hypoglycemia in E-I 4 (Tamrakar et al. 2015) . These results suggest that estradiol may enhance glycolytic yield of ATP and NADH, while diminishing mitochondrial fuel catabolism and aerobic respiration in the aftermath of this stress. In contrast, augmentation of basal ATP synthase-α protein expression in post-hypoglycemic OVX+oil rats implies that, in the absence of estradiol, increased energy output may occur via oxidative phosphorylation as A2 cells recover from hypoglycemia. In Est/I 4 group, renewed exposure to hypoglycemia, e.g. induction of a fourth daily bout, did not further modify A2 PFKL expression relative to the heightened day four baseline, suggesting that the glycolytic pathway may adopt a heightened steady-state that is refractory to recurring hypoglycemic episodes. Re-exposure to hypoglycemia on day four suppressed the 55 kDa PDH complex subunit protein E2/E3 pb below baseline in A2 cells from both estradiol-and oil-implanted OVX rats, an acquired negative response that is estrogen-independent. A2 neurons may thus develop a lesser need for glycolysis-derived substrate for mitochondrial aerobic respiration during recurring hypoglycemia. A fourth hypoglycemic bout did not elevate A2 ATP synthase-α protein levels relative to now-diminished basal profiles in E-I 4 , but suppressed this protein below baseline in O-I 4 , inferring that mitochondrial energy production may adaptively down-regulate in the latter treatment group. Since acute hypoglycemia did not modify ATP synthase-α expression in E or O (Tamrakar et al. 2015) , current results infer continuation of this lack of response in E-I 4 and development of negative reactivity in O-I
4 . Results also demonstrate sustained hypoglycemic up-regulation of the tricarboxylic acid cycle enzyme OGDH in E-I 4 rats, but inhibition of this protein profile by recurring hypoglycemia in O-I 4 , amounting to gain of negative response. These findings suggest that estradiol may promote an ongoing need for non-energy derivative Krebs cycle products. It should be noted that up-or down-regulation of A2 enzyme protein expression is not automatic proof of corresponding increases and decreases in enzyme activity; however, prior evidence for correlated increases in metabolic enzyme expression and activity due to estradiol treatment supports the plausibility of that outcome (Irwin et al. 2008) . Affirmation of effects of recurring hypoglycemia on basal and hypoglycemic patterns of A2 enzyme activity awaits the development of analytical methods of requisite sensitivity for analysis of small-size neuron pool samples equivalent to those evaluated here.
Acclimation of A2 neuron AMPK and upstream kinase and phosphatase protein expression to hypoglycemia: impact of estradiol Precedent hypoglycemia did not modify day four baseline pAMPK protein profiles in A2 neurons from estradiol-or oil-implanted OVX rats. In the absence of correlative information on post-hypoglycemic A2 cell ATP content, we speculate that steady-state energy levels in these cells may be preserved despite adaptive changes in energy pathway enzyme expression. ATP stores are likely to remain unchanged if net increases or reductions in ATP output are matched by parallel up-or downsizing of energy utilization. During the fourth of four hypoglycemia bouts, A2 pAMPK protein levels were elevated in both E-I 4 and O-I 4 , albeit to a significantly greater extent in the latter. These results suggest that precedent hypoglycemia may render A2 neurons vulnerable to energy instability during re-exposure, but that extent of energy deficiency may be attenuated by estradiol. We previously reported that estradiol promotes deactivation of AMPK during chronic hypoglycemia (Cherian and Briski 2012) . A critical difference between that study and the present work studies is improved sensitivity of immunocytochemical methodology for identification of cDVC TH-ir neurons in hindbrain cryosections, as reflected by higher numbers of collectable A2 cells per individual animal, resulting in sufficient numbers of pools for quantitative protein analysis in the present research. Thus, prior results may reflect, in part, the distinctive reactivity of a subset of A2 cells characterized by relatively high neurotransmitter content. Estradiol may function to prevent adaptation of upstream AMPK-regulating protein kinase and phosphatase enzymes to recurring hypoglycemia. A fourth of four hypoglycemic bouts did not modify A2 CaMMκβ protein content in E-I 4 or O-I 4 , but diminished PP2A levels only in the former group. As a single hypoglycemic episode was previously observed to increase CaMMκβ and reduce PP2A protein profiles in OVX+oil rats (Tamrakar et al. 2015) , current data suggest that when estradiol is absent, precedent exposure eliminates these responses. As we did not directly compare incremental changes in AMPK activity in acute vs. chronic hypoglycemic rats, we do not know if precedent hypoglycemia alters the magnitude of A2 energy debilitation in OVX+oil rats. In light of aforementioned adaptive loss of facilitative kinase and inhibitory phosphatase protein responses to renewed hypoglycemia in O-I 4 rats, cellular reductions in ATP may play a relatively greater role in AMPK activation during recurring vs. acute hypoglycemia in that group. Precedent hypoglycemia did not alter basal A2 ACC or pACC protein profiles in E-I 3 V 1 , but respectively increased or decreased these proteins in O-I 3 V. These data imply that when estradiol is absent, ACC activity may be enhanced amidst bouts of repeated hypoglycemia; the possibility that this outcome coincides with augmented cellular malonyl CoA accumulation and decreased fatty acid oxidation awaits experimental verification. Renewed hypoglycemia on day four elevated both profiles in E-I 4 without effect in O-I 4 , suggesting that in the latter this enzyme acquires a new state of heightened activity that is refractory to recurring hypoglycemia. A potential ensuing lack of change in malonyl CoA levels may impede fatty acid utilization for energy. Acute hypoglycemia had no effect on ACC, pACC, or FAS protein profiles in estradiol-or oil-implanted OVX rats (Tamrakar et al. 2015) ; current observations of concurrent augmentation of ACC and FAS protein profiles in the E-I 4 group imply a gain in positive reactivity of these proteins in this group.
As the DVC is comprised of multiple neuron neurotransmitter phenotypes, analyses of mitochondrial complex enzyme protein subunit expression in whole DVC samples shed light on whether patterns of A2 nerve cell protein adaptation to recurring hypoglycemia are representative or uncommon in this neural structure.
For example, DVC PDH-E2 and PDH-E1-α subunit protein profiles acquire negative reactivity in E-I 4 but not O-I 4 ; yet, A2 PDH-E2 protein is down-regulated by acclimation in both E-I 4 and O-I 4 , inferring that negative A2 adaptation in the absence of estradiol is atypical of the DVC. DVC and A2 neuron samples also showed differential habituation of the Complex II subunit C-V-alpha, as baseline expression of this protein was respectively unchanged or decreased in these samples from E-I 3 V rats, and recurring hypoglycemia increases protein levels in A2 neurons but not whole DVC in O-I 4 . Precedent hypoglycemia elevated synthase-α protein in the O-I 3 V DVC and O-I 3 V A2 neurons, but decreased this protein in E-I 3 VA2 cells. Observations of estradiol-mediated augmentation of basal DβH protein expression concur with evidence that estrogen stimulates DβH mRNA expression in rat brain (Senova et al. 2002) . Modifications in A2 DβH protein levels in estradiol-vs. oil-treated rats one day following serial exposure to hypoglycemia reflect a persistent impact of that prior experience on baseline catecholamine biosynthesis despite recovery from hypoglycemia. Data demonstrating a decline vs. increase in this protein profile in E-vs. O-I 3 V groups concur with previous reports of divergent changes in A2 DβH mRNA after precedent hypoglycemia (Cherian and Briski 2012) , implying that neurotransmitter production may be reduced or augmented between bouts of recurring hypoglycemia, at least within post-recovery time frame examined here. It should be noted that protein analyses were performed 2 hr after initiation of the final hypoglycemic episode; thus, the possibility (particularly in the presence of estrogen) that DβH levels measured at this time point may reflect rebound from a preceding stimulatory response that occurred between time zero and sampling, while this protein profile remains elevated in the absence of estradiol cannot be discounted. Further research is needed to evaluate ramifications of estradiol-dependent acclimation of between-hypoglycemia A2 nerve cell signaling on neural functions controlled by this cell group. Exacerbation of adjustments in baseline DβH protein expression by a fourth daily hypoglycemic episode implies that potential deviations in A2 noradrenergic signaling may be corresponding heightened during renewed exposure to this metabolic stress. Hypoglycemia poses a significant risk of brain injury as a continuous glucose supply is needed to provide sufficient energy to maintain neuron transmembrane ion gradients. Rigorous glycemic control is crucial for ideal management of insulin-dependent diabetes mellitus (IDDM), but is complicated by recurring iatrogenic insulin-induced hypoglycemia (Cryer 2008 (Cryer , 2011 . In IDDM patients, recurring hypoglycemia elicits hypoglycemia-associated autonomic failure, which results in severe, unrelieved hypoglycemia due to maladaptive diminishment of glucose counter-regulatory outflow and neurogenic unawareness (Cryer 2005) . Current results bolster the need for additional research to investigate effects of adaptive down-vs. up-regulation of A2 nerve cell signaling in the presence vs. absence of estradiol on metabolic as well as non-metabolic functions that rely upon in input from this cell group between and during bouts of ongoing hypoglycemia in patients prone to this therapy complication.
Acclimation of A2 neuron DβH enzyme protein expression to hypoglycemia: impact of estradiol
This study did not affirm our prediction of parallelism of adaptation of A2 nerve cell DβH protein expression and DVC Fos immunolabeling (Nedungadi et al. 2006) in both estradiol-and oil-implanted OVX rats. Rather, evidence for divergence of these two parameters, independent of estradiol status, detracts from our working assumption that hypoglycemia-induced DVC Fos immunoreactivity is a reliable indicator of metabolo-sensory neuron signaling. Further work is needed to identify AP-1 -controlled nerve cell transcriptional activities that habituate in an estradiol-dependent manner to precedent hypoglycemia and consequent effects on A2 function.
The female lifespan includes transition between different reproductive states, e.g. juvenile quiescence, fecundity, and senescence, typified by unique patterns of ovarian estrogen secretion. Current results emphasize the need to understand how dissimilar physiological patterns of estradiol output, including variations in hormone secretion that occur over estrous cycle and pregnancy, as well as states of low estrogen output before and after fecundity may influence A2 neuron energetic habituation to recurring hypoglycemia.
CONCLUSIONS
The present studies demonstrate that estradiol permits amplification of A2 nerve cell expression of key glycolytic, Krebs cycle, oxidative phosphorylation, and acetyl CoA-FAS pathway enzyme proteins during recurring hypoglycemia. Between hypoglycemic bouts, A2 cells may acquire, when estradiol is present, heightened needs for glycolytic metabolites or derived energy, coincident with decreased reliance upon oxidative phosphorylation. Estrogen-mediated prevention of maladaptive decline in ODGH and ATP synthase-α expression during recurring hypoglycemia may contribute to energetic resilience to this persistent metabolic insult. Opposite direction of DβH habituation to recurring hypoglycemia in estradiolvs. non-steroid-replaced OVX female rats implies that potential acclimation of A2 signaling to this stress is hormone-dependent.
